Keryx Biopharmaceuticals (KERX) Earning Positive Press Coverage, Analysis Finds

Press coverage about Keryx Biopharmaceuticals (NASDAQ:KERX) has been trending positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Keryx Biopharmaceuticals earned a daily sentiment score of 0.29 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.4223184984699 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) traded down $0.09 during midday trading on Wednesday, reaching $4.47. 1,560,600 shares of the company’s stock traded hands, compared to its average volume of 1,534,529. The company has a quick ratio of 3.76, a current ratio of 4.46 and a debt-to-equity ratio of 13.95. Keryx Biopharmaceuticals has a 1 year low of $4.33 and a 1 year high of $8.38.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.03). The firm had revenue of $15.00 million for the quarter, compared to analyst estimates of $18.88 million. Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 323.92%. The company’s quarterly revenue was up 138.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.39) earnings per share. research analysts expect that Keryx Biopharmaceuticals will post -1.36 earnings per share for the current year.

Several equities analysts recently commented on KERX shares. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 16th. ValuEngine downgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, November 10th. Stifel Nicolaus dropped their price objective on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating for the company in a research note on Wednesday, November 8th. Finally, BidaskClub raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. Keryx Biopharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $7.35.

COPYRIGHT VIOLATION WARNING: “Keryx Biopharmaceuticals (KERX) Earning Positive Press Coverage, Analysis Finds” was published by Week Herald and is owned by of Week Herald. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Insider Buying and Selling by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply